NCT00423410View on ClinicalTrials.gov

A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

April 30, 2009

Study Completion Date

September 30, 2009

Conditions
Advanced Cancer
Interventions
DRUG

EPC2407 (crinobulin)

IV infusion 1 to 4 hours

Trial Locations (3)

85258

Scottsdale Healthcare, Scottsdale

90211

Tower Oncology Research, Beverly Hills

92093

Rebecca and John Moores UCSD Cancer Center, San Diego

Sponsors
All Listed Sponsors
lead

EpiCept Corporation

INDUSTRY